Updated Jul 16, 2026
Sullivan Timothy Eugene has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.56M.
Timothy Eugene Sullivan is the Chief Financial Officer of Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for diseases with high unmet medical needs. He has been involved in the company's financial operations and strategic planning.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 58.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 34.4K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 11.9K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 6.9K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 58.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 58.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 29.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 29.1K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 30.6K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 30.6K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 41.2K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 41.2K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 71.5K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 140.9K | — | |
| 2026-04-20 | APLS | Apellis Pharmaceuticals, Inc. | G — Bona-fide gift | 11.1K | $0.00 | |
| 2026-04-20 | APLS | Apellis Pharmaceuticals, Inc. | G — Bona-fide gift | 11.1K | $0.00 | |
| 2026-01-30 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 58.1K | $0.00 | |
| 2026-01-23 | APLS | Apellis Pharmaceuticals, Inc. | S — Open-market sale | 10.3K | $21.77 | $224K |
| 2026-01-21 | APLS | Apellis Pharmaceuticals, Inc. | S — Open-market sale | 2.9K | $19.79 | $57K |
| 2026-01-15 | APLS | Apellis Pharmaceuticals, Inc. | S — Open-market sale | 3.9K | $22.19 | $86K |
Timothy Eugene Sullivan is the Chief Financial Officer of Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for diseases with high unmet medical needs. He has been involved in the company's financial operations and strategic planning.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($1.56M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Sullivan Timothy Eugene profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.